Patients with stable coronary artery disease and diabetes with previous percutaneous coronary intervention (PCI), particularly those with previous stenting, are at high risk of ischaemic events. These patients are generally treated with aspirin.
In a large (11,154 patients enrolled) phase 3, placebo-controlled, multicentric (1315 sites in 42 countries) randomised trial. the Authoras aimed to investigate if these patients would benefit from treatment with aspirin plus ticagrelor.
The results show that long-term therapy with ticagrelor in addition to aspirin should be considered in patients with diabetes and a history of PCI who have tolerated antiplatelet therapy, have high ischaemic risk, and low bleeding risk.